Spots Global Cancer Trial Database for Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer

Official Title: Imaging Biomarkers in Pancreatic and Hepatobiliary Cancers

Study ID: NCT02361320

Conditions

Pancreatic Cancer

Interventions

Computed Tomography (CT)

Questionnaire

Study Description

Brief Summary: This trial studies how well computed tomography works in diagnosing patients with pancreatic or hepatobiliary cancer. Computed tomography may help researchers predict how patients with pancreatic or hepatobiliary cancer may respond to chemotherapy.

Detailed Description: PRIMARY OBJECTIVES: I. To prospectively validate our pilot data that indicate that pre-therapy computed tomography-based (CT) mass transport properties correlate with overall survival. II. To prospectively validate our pilot data that indicate that local control of pancreatic and hepatobiliary tumors correlate with changes in computed tomography-based mass transport properties of the tumors after cytotoxic therapies. OUTLINE: Patients undergo CT scan at baseline and after 4 to 6 cycles of fluorouracil/irinotecan/leucovorin calcium/oxaliplatin, or after 4 infusions of gemcitabine/nab-paclitaxel (or other gemcitabine-based regimens), or 6 to 12 weeks after radiotherapy for hepatobiliary cancers. Patients may undergo optional magnetic resonance imaging (MRI) scans prior to therapy, after two weeks of therapy, and at the time of the first restaging CT scan.